Désiré Collen, Selected papers

List of selected papers

A list of 14 research papers, 4 review articles and 3 US patents, selected for their relevance, are individually reproduced below.

RESEARCH PAPERS

Collen D.

Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur. J. Biochem. 69, 209-216, 1976.
(355 times cited).

Discovery of the main plasmin inhibitor in blood, later named alpha2-antiplasmin.

Wiman B., Collen D.

On the kinetics of the reaction between human antiplasmin and plasmin. Eur. J. Biochem. 84, 573-578, 1978.
(320 times cited).

Quantitation of the reaction rate between plasmin and alpha2-antiplasmin and of the role of the lysine binding site in plasmin.

Rijken D.C., Collen D.

Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J. Biol. Chem. 256, 7035-7041, 1981.
(807 times cited).

First purification of human tissue-type plasminogen activator from a malignant cell line allowing larger scale production for biochemical, preclinical and clinical studies.

Matsuo O., Rijken D.C., Collen D.

Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 291, 590-591, 1981.
(245 times cited).

First demonstration of the thrombolytic effect of tissue-type plasminogen activator in an experimental animal model.

Hoylaerts M. Rijken D.C., Lijnen H.R., Collen D.

Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J. Biol. Chem. 257, 2912-2919, 1982.
(1233 times cited).

Quantitation of the activation rate of plasminogen by  tissue-type plasminogen activator and of the accelerating role of fibrin.

Pennica D., Holmes W.E., Kohr W.J., Harkins R.N., Vehar G.A., Ward C.A., Bennett W.F., Yelverton E., Seeburg P.H., Heyneker H.L., Goeddel D.V., Collen D.

Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301, 214-221, 1983.
(1214 times cited).

Cloning and sequencing of complementary DNA (cDNA) of human tissue-type plasminogen activator.

Bergmann S.R., Fox K.A.A., Ter-Pogossian M.M., Sobel B.E., Collen D.

Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science 220, 1181-1183, 1983. 
(229 times cited).

First demonstration of the thrombolytic effect of tissue-type plasminogen activator in an animal model of acute myocardial infarction and its beneficial effect on infarct size.

 

Van de Werf F., Ludbrook P.A., Bergmann S.R., Tiefenbrunn A.J., Fox K.A.A., De Geest H., Verstraete M., Collen D., Sobel B.E.

Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N. Engl. J. Med. 310, 609-613, 1984.
(371 times cited).

First demonstration of the thrombolytic effect of purified natural tissue-type plasminogen activator in patients with acute myocardial infarction.

Collen D., Topol E.J., Tiefenbrunn A.J., Gold H.K., Weisfeldt M.L., Sobel B.E., Leinbach R.C., Brinker J.A., Ludbrook P.A., Yasuda T., Bulkley B.H., Robison A.K., Hutter A.M., Bell W.R., Spadaro J.J., Khaw B.A., Grossbard E.B.

Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 70, 1012-1017, 1984.
(411 times cited).

First randomized trial with recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.

Lijnen H.R., Van Hoef B., De Cock F., Okada K., Ueshima S., Matsuo O., Collen D.

On the mechanism of fibrin-specific plasminogen activation by staphylokinase.
J. Biol. Chem. 266, 11826-11832, 1991.
(151 times cited).

Elucidation of the unique mechanism of  the fibrin-selective activation of plasminogen by staphylokinase in human plasma.

Collen D., Van de Werf F.

Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.Circulation 87, 1850-1853, 1993.
(118 times cited).

First use of recombinant staphylokinase in patients with acute heart attack.

Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J.J., Collen D., Mulligan R.C.

Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368, 419-424, 1994.
(891 times cited).

Generation of mice with inactivated genes encoding the plasminogen activators t-PA and/or u-PA and characterisation of their phenotypes.

Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A.

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439, 1996.
(2988 times cited).

First demonstration that inactivation of a single copy of the VEGF gene results in intra uterine death.

 

Nagai N., Demarsin E., Van Hoef B., Wouters S., Cingolani D., Laroche Y., Collen D.

Recombinant human microplasmin: Production and potential therapeutic properties. J. Thromb. Haemost. 1, 307-313, 2003.
(72 times cited).

Production in the yeast Pichia pastoris and characterization of recombinant human microplasmin suitable for clinical use.

reviews

Collen D.

On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.Thromb. Haemost. 43, 77-89, 1980.
(1225 times cited).

A review of the state of the art knowledge of the human plasma fibrinolytic system in 1979.

Collen D.

Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nature Med. 4, 279-284, 1998.
(114 times cited).

A review of the unique molecular mechanism of the fibrin-selective activation of plasminogen by staphylokinase and of its clinical potential for thrombolytic therapy.

Collen D.

The plasminogen (fibrinolytic) system. Marian Barnhart Lecture. Thromb. Haemost. 82, 259-270, 1999.
(296 times cited).

A review of the state of the art knowledge of the human plasma fibrinolytic system in 1999.

Collen D., Lijnen H.R.

Tissue-type plasminogen activator: a historical perspective and personal account. J. Thromb. Haemost. 2, 541-546, 2004.
(79 times cited).

A review of the plasma fibrinolytic system from a historical and personal perspective.

PATENTS

Collen D., Rijken D., Matsuo O.

Plasminogen activator and pharmaceutical composition having thrombolytic activity.
US 4,752,603 June 21, 1988.

The “t-PA Patent” licensed by KU Leuven (LR&D) to Genentech Inc, South San Francisco, CA.

Collen D., Stassen J.M., Lijnen H.R.

Use of Staphylokinase for the preparation of a pharmaceutical composition for treating arterial thrombosis.
US 5,336,495 August 9, 1994.

Patent describing the preparation and characterization of clinical grade recombinant staphylokinase for thrombolytic therapy in man.

Collen D., Nagai N., Laroche Y.

Yeast expression vector and a method of making a recombinant protein by expression in a yeast cell.
US 7,445,775 B2 November 4, 2008.

Patent describing the preparation and characterization of recombinant microplasmin for human use.